Edwards has studied Resilia in two pre-market clinical trials, combining outcomes for a total of 904 patients and more than 3,800 patient years of follow-up that support the tissue replacement platform.
Are we taking about Edward’s 904/3800 patients vs AVR’s 5 patients and another 5 in the wing?
If it’s the case it is understandable why the big companies are not interested in AVR products as yet,
A timeline going forward would be greatly appreciated, page-91
-
- There are more pages in this discussion • 48 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.20 |
Change
-0.010(0.10%) |
Mkt cap ! $215.6M | |||
| Open | High | Low | Value | Volume |
| $10.20 | $10.26 | $9.81 | $396.9K | 39.44K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1200 | $10.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.20 | 966 | 1 |
View Market Depth
| Last trade - 16.10pm 05/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |